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Abstract
Background: Over the last decade a number of species, from farm animals to rodents, have been cloned using somatic cell
nuclear transfer technology (SCNT). This technique has the potential to revolutionize the way that genetically modified
animals are made. In its current state, the process of SCNT is very inefficient (,5% success rate), with several technical and
biological hurdles hindering development. Yet, SCNT provides investigators with powerful advantages over other
approaches, such as allowing for prescreening for the desired level of transgene expression and eliminating the excess
production of undesirable wild-type animals. The rat plays a significant role in biomedical research, but SCNT has been
problematic for this species. In this study, we address one aspect of the problem by evaluating methods of activation in
artificially constructed rat embryos.
Principal Findings: We demonstrate that treatment with a calcium ionophore (ionomycin) combined with a variety of
cyclin-dependent kinase inhibitors is an effective way to activate rat embryos. This is in contrast to methods developed for
the mouse embryo, which tolerates much less specific chemical treatments. Methods developed to activate mouse embryos
do not translate well to rat embryos.
Conclusions: Activation methods developed for one species will not necessarily translate to another species, even if it is
closely related. Further, the parthenogenic response to chemical activators is not always a reliable indicator of how
reconstructed embryos will react to the same activation method. A better understanding of rat oocyte physiology, although
essential for developing better models of disease, may also provide insights that will be useful for making the SCNT process
more efficient.
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Introduction
The modeling of disease processes in vitro (e.g., in cultured cells)
and through the use of computer simulations is currently far from
sufficient to mimic both the systemic effects of new drugs and the
complex symptomology of most diseases. Unfortunately, many
human diseases have no counterpart in other species. This is a
major obstacle to the understanding of disease progression and the
development of therapeutics. For these reasons, genetically
modified animals expressing one or more disease genes are a vital
resource for both the academic and private sectors, and are an
indispensible research tool for advancing our understanding of
both basic biology and human disease. Currently, the most
common genetically modified mammalian model is the mouse. A
simple PubMed search of reports of genetically modified animals
indicates that ,97% of the total involve mice.
However, the mouse is not always the ideal option for
biomedical research. There are many situations where a
genetically modified rat is a preferred model. The first and
simplest consideration is size. The rat is larger, making it better
suited for microsurgical manipulation, and it provides more tissue
for analysis. Second, rats are preferred for research involving
behavioral tests [1], an essential consideration for modeling
psychiatric and neurological disorders. Rats are also essential for
ADMET (Absorption, Distribution, Metabolism, Excretion, and
Toxicity) testing, and for basic physiological studies. Finally, for a
variety of reasons, modeling some biological processes in mice
often fails to adequately mimic the situation in humans. As just one
example, the cytokine interferon-c (IFNc) exacerbates multiple
sclerosis in humans [2] and in the corresponding rat model
(experimental autoimmune encephalomyelitis) [3]. In contrast,
IFNc has a protective effect in the mouse experimental
autoimmune encephalomyelitis model [4]. Thus, the rat model
of multiple sclerosis predicts the human response while the mouse
model gives the opposite result.
The vast majority of rodent disease models are generated by the
process of pronuclear microinjection (PMI) [5]. This process
requires the injection of DNA directly into the pronucleus of a
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pseudopregnant mothers for development. Only 10–20% of the
resulting offspring will likely express the transgene; of these,
approximately 70% will transmit the transgene through the germ
line, making them suitable colony founding animals. The situation
becomes more complex when the size of the transgene construct
increases. This affects the number of copies that integrate, with a
huge range of possibilities: from one to five copies for large
transgenes, to several hundred for small transgenes (reviewed in
[6]). The investigator has little control over such parameters, and a
true assessment of success cannot begin until the animals are born,
at which point transgene expression and development of the
desired phenotype can be evaluated.
Over the past several years, somatic cell nuclear transfer
(SCNT) has proven to be a viable alternative to PMI
[7,8,9,10,11,12,13,14]. This process involves transfer of a somatic
cell nucleus into a cytoplast (enucleated oocyte), which must be
artificially activated to drive the developmental regime from the
single celled oocyte to the whole organism [15]. Using SCNT the
investigator specifically selects the genetically modified clonal cell
line that will be the source of nuclear material from which to
generate a complete animal. Thus, rather than being forced to rely
on chance, the investigator has the ability to choose the desired
modification or level of expression in advance. This can be
critically important if either high levels of expression are necessary
to obtain a phenotype, or if the desired model is a targeted
alteration in a specific gene (knock-in or knock-out). The ability to
screen the cell line for the genetic modification of the investigator’s
choice gives unparalleled control over the characteristics of the
founding animal. This is a major advantage over pronuclear
microinjection, where expression of a transgene is highly variable
and difficult to control, or in the generation of chimeras from
modified embryonic stem (ES) cells.
All animals produced using SCNT will be genetically modified.
Nontransgenics are not created in SCNT, since all of the
procedural inefficiency occurs during in vitro manipulation or
through the loss of reconstructed embryos in utero. Thus, SCNT
results in a reduction in the number of animals that have to be
euthanitized, one of the three Rs of animal research (reduction,
refinement and replacement), working towards the goal of
improving the humane treatment and use of experimental
animals.
In spite of the potential advantages of rat models of human
disease, few actually exist. Although the second most common
transgenic mammal after the mouse, the rat is still highly under
utilized, outnumbered by mice almost 50:1 in the PubMed
database. Although PMI was originally developed for mouse
embryos, the technology was adapted for generation of genetically
modified rats in the 1990s. However, increased space and cost
requirements often limit the production of genetically modified
rats in this manner [16]. Also, standard SCNT has proven to be
very difficult to implement in the rat [17,18,19,20,21,22,23]. To
date, only a single report [24] exists describing the successful
generation of a rat by this method.
Many factors contribute to these inefficiencies, including
inadequate culture conditions for rat embryos (known to
spontaneously activate) [25], variations in efficiency using
different cell types as donors of either nuclear material and/or
cytoplasts [19,26], inefficient means of activation, and countless
others. In this study, we address one of the major obstacles to the
successful generation of genetically modified rats by SCNT, the
poor efficiency of embryo activation. We report that rat embryos,
unlike those of mice, require more selective forms of chemical
treatment.
Materials and Methods
Animals
Long Evans Hooded (LEH) rats, approximately 2–3 months
old, from Harlan Laboratories (Indianapolis, IN) were used as
oocyte donors. Mice (B6C3F1, 3–4 weeks old) were used for
comparison experiments. Animals were housed in an environ-
mentally controlled room with a 14:10 hour light:dark cycle and
given food and water ad libitum.
Ethics Statement
All animal work was conducted with prior IACUC approval,
and was performed in accordance with USDA and PHS
guidelines.
Oocyte Collection
Female LEH rats were injected intraperitoneally with 40 I.U.
pregnant mare serum gonadotropin (PMSG) between 5:00 and
6:30pm and 40 I.U. human chorionic gonadotropin (hCG)
approximately 48 hours later. Rats (typically 3–4/experiment)
were euthanitized 15–16 hours post hCG by CO2 asphyxiation
followed by decapitation. We determined in a pilot study that this
time point minimizes spontaneous activation in rat oocytes
(spontaneous activation rate, determined by abortive division on
overnight culture: 15–16 hours, 7/74, 9.5%; 17–18+ hours, 24/
112, 21.4%). We were unable to reliably obtain oocytes at
14 hours or less post hCG in the rat. Mice received a lower
hormone dose (5 I.U. PMSG/5 I.U. hCG). Oviducts were
removed from the females into a prewarmed dish of potassium
simplex optimized media (KSOM) with 10 mM HEPES (flushing
and handling media, or FHM; Millipore, Danvers, MA). Ampullae
were torn with forceps and cumulus cell oocyte complexes moved
into a dish containing KSOM and hyaluronidase (1 mg/mL;
Sigma-Aldrich, St. Louis, MO), which was then placed into a 5%
CO2 incubator at 37uC for 5–6 minutes. Remaining cumulus cells
were removed by gentle pupating. Denuded oocytes were washed
approximately ten times by moving them sequentially through
50 mL drops of KSOM containing 5 mg/mL cytochalasin B (CB;
EMD Biosciences, Gibbstown, NJ) [27].
Oocyte Enucleation and Embryo Reconstruction
After collection and washing, oocyte chromosomes were
aspirated using a piezo impact micromanipulator (PrimeTech
PMM-150FU; Eppendorf, Hauppauge, NY) and a pulled glass
micropipette connected to a Cell Tram Vario (Eppendorf). In
some cases, enucleation was confirmed by brief exposure to UV
light after staining with Hoechst 33342 (Sigma-Aldrich). Accuracy
of enucleation was .95% (3 independent experiments: 15/16, 36/
36 and 43/44 enucleated successfully; Figure 1). Unenucleated
oocytes used in parthenogenic activation experiments were washed
to remove hyaluronidase and then placed back into the incubator
(at 37uC) for two hours. This incubation was intended to mimic
the time required for oocyte enucleation and reconstruction
through SCNT.
Embryonic fibroblasts (either rat or mouse, where applicable)
were inserted into the perivitelline space with the same pipette
used for enucleation. The oocyte-fibroblast complexes that did not
spontaneously lyse after 30 minutes at 37uC were sequentially
equilibrated by moving them through drops of 25%, 50%, and
75% fusion medium (0.25 M D-sorbitol, 0.1 mM CaOAc,
0.5 mM MaOAc, 0.1% BSA) diluted in KSOM prior to
placement in the fusion chamber. Oocyte-fibroblast complexes
were arranged such that the fibroblast in the perivitelline space
was perpendicular to the electrodes. Fusion was stimulated by an
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wave DC pulse (3.3–3.8 kV/cm DC, 10–15 ms), followed by an
additional AC pulse to stabilize membrane contact (8–10 V AC,
5 s). We were also able to achieve fusion in more conductive
medias (25 mM NaHCO3 or Na2HPO4, 0.1 mM CaCl2, 3.2 mM
KCl, 96 mM NaCl; DC pulse of 1.2 kV/cm, 20 ms, with no AC
pulse). Fusion was performed with a 1 mm electrode separation
using an ECM2001 electro cell manipulator connected to an
Enhancer 400 oscilloscope (BTX; Holliston, MA) in order to
precisely control conditions (Figure 2). After the electrical pulse,
oocyte-fibroblast complexes were left in the fusion chamber for 10
minutes and were then moved to KSOM media. Fusion was
assessed following a 30 minute incubation at 37uC. Oocyte-
fibroblast complexes that did not fuse were re-equilibrated in the
fusion buffer and the electrical stimulation repeated. Reconstruct-
ed embryos were washed several times and then placed into drops
containing various types of activation media.
Activation of Collected Oocytes
Following the incubation period, the oocytes were moved
sequentially through multiple 50 mL drops of FHM, and then
divided into groups. Activation treatments were all conducted in
the 37uC incubator. Basic activation conditions consisted of (alone
or in combination): 10 mM SrCl2 (Sigma-Aldrich) for 3 hours,
5 mM ionomycin (EMD biosciences) for 15 minutes, or 2 mM 6-
dimethylaminopurine (DMAP; Sigma-Aldrich) for 2–3 hours.
Time of exposure was based on published studies, or in cases
where no comparable studies were available, on small scale pilot
experiments. Exposure to SrCl2 is a commonly used method of
activating murine oocytes [28,29]. Ionomycin treatment is thought
to mimic the intracellular calcium spike that occurs immediately in
the oocyte following fertilization [30]. Incubation with a calcium
ionophore such as ionomycin followed by the general phospho-
kinase inhibitor DMAP has been used successfully in multiple
species, including successful SCNT in both cattle [14] and goats
[31]. DMAP is believed to induce activation by preventing the
phosphorylation of cdc25, which is normally responsible for
activating maturation promoting factor, or MPF [30]. Since
DMAP is relatively nonselective, we also tested the activation
efficacy of 3 different cyclin dependent kinase inhibitors (CDKIs;
100 mM, 4–6 hours): bohemine [32], roscovitine [33], and
butyrolactone [24]. Hence, our range of activation conditions
covered a broad spectrum, from the relatively crude addition of
strontium to the media, to the relatively specific treatment with
CDKIs. Following the activation procedure, embryos were washed
at least 10 times and placed in drops of KSOM (for mouse
embryos) or mR1ECM (modified rat 1-cell embryo culture
medium, for rat embryos) for further development in vitro
[24,34]. Activation state was assessed ,24 hours later. Activation
was defined as the number of embryos to undergo at least a first
stage cleavage (to 2-cell embryo). Embryos that had undergone an
additional cleavage to 4-cell were pooled with the 2-cell embryos
to determine the total number activated. Statistical significance
was determined using the x
2 test, corrected for multiple
comparisons by the Holm-Bonferroni method [35].
Figure 1. Generating cytoplasts by oocyte enucleation. Prior to
insertion of a foreign nucleus, the native genetic material is removed
from the oocyte. Enucleation can be performed without the use of
fluorescent dyes; oocytes shown were first enucleated, and then briefly
stained with Hoechst 33342 to determine efficiency. The same oocytes
are shown for both phase contrast and fluorescence microscopy (left
and right panels, respectively). The metaphase plate is clearly visible in
all 5 examples of unenucleated oocytes (shown by arrows), with no
staining evident in any of the enucleated cells.
doi:10.1371/journal.pone.0009799.g001
Figure 2. Example of electrofusion of rat fibroblasts with
enucleated cytoplasts. A series of bright field photomicrographs are
shown over the span of 10 minutes in the fusion chamber after the
administration of the electrical pulse (arrows indicate the position of the
fibroblasts at time zero). In this case, fusion is essentially complete after
10 minutes.
doi:10.1371/journal.pone.0009799.g002
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We first tested methods known to work reasonably well for the
activation of mouse embryos (Table 1). Strontium was an effective
means of activation [x
2
(1)=5.66, p,0.05], for both parthenogenic
mouse embryos and for those that were reconstructed following
enucleation and electrofusion. Ionomycin followed by DMAP
(I+DMAP) treatment also worked well [x
2
(1)=6.60, p,0.05].
Overall effectiveness of activation did not differ between
parthenotes and reconstructed embryos in the mouse. However,
although we were able to culture mouse parthenotes to the
blastocyst stage (38.1%) following both strontium [x
2
(1)=6.78,
p,0.05] and I+DMAP [x
2
(1)=9.45, p,0.05] activation, a much
smaller fraction of reconstructed embryos (7.5%) were able to
develop to this point [x
2
(1)=9.30, p,0.05]. Only reconstructed
mouse embryos activated with strontium developed to the
blastocyst stage. However, preliminary tests in rat embryos
indicated that strontium failed as a means to activate reconstructed
rat embryos. This lead us to pursue other methods of activation.
We decided to refine the I+DMAP treatment, which is a
moderately more targeted activation treatment than strontium
exposure. DMAP is relatively nonspecific, blocking numerous
other kinase activities, and can lead to the abnormal mobilization
of cytoskeletal components and premature mitosis [36,37]. We
reasoned that we might achieve better results by substituting more
specific cyclin-dependent kinase inhibitors (CDKIs) in the place of
DMAP. We selected bohemine [32], roscovitine [33], and
butyrolactone [24], which are purine analogs that bind within
the ATP binding pocket. This mimics the sperm induced down-
regulation of cytostatic factor(s) that are responsible for maintain-
ing levels of MPF, leading to the proteolytic degradation of cyclin
B and subsequently allows the oocyte to complete the second
meiotic division and begin development [30]. Good rates of
activation were achievable with roscovitine [x
2
(3)=13.1, p,0.05],
starting at a concentration of 50 mM[ x
2
(1)=8.1, p,0.05] to
100 mM[ x
2
(1)=9.85, p,0.05] (Figure 3), even though roscovitine
is typically used at lower concentrations [38,39]. Similar results
were obtained with bohemine (not shown).
We selected a concentration of 100 mM to compare the three
CDKIs, alone or in combination with ionomycin, as a means of
activating rat parthenotes (Figure 4). Ionomycin treatment alone
failed as a means of activation. CDKI treatment alone was able to
activate rat oocytes [36.1%; x
2
(3)=15.5, p,0.01]. Although
butyrolactone was the most potent activator [65.3%; x
2
(1)=10.7,
p,0.01], there were no significant differences between any of the
three CDKIs. Pretreatment with ionomycin significantly improved
activation [68.3%; x
2
(3)=11.6, p,0.01]. Bohemine [81.4%;
x
2
(1)=13.7, p,0.01], roscovitine [75.5%; x
2
(1)=12.8, p,0.01]
and butyrolactone [81.8%; x
2
(1)=14.9, p,0.01] were all equally
potent.
Table 1. Mouse Oocyte Activation.
Parthenogenic:
Treatment Activated Blastocyst
None 18/65 (27.7) 0/18 (0.0)
Sr
2+ 23/57 (40.4) 10/23 (43.5) *
I + DMAP 22/63 (34.9) 14/22 (63.6) *
Reconstructed:
Treatment Activated Blastocyst
None 1/18 (5.6) 0/1 (0.0)
Sr
2+ 24/42 (57.1) * 4/24 (16.7)
I + DMAP 28/37 (75.7) * 0/28 (0.0)
Activation data are numbers of normal appearing 2–4 cell embryos after
24 hours/total (%). Number of blastocysts with a defined inner cell mass were
determined following 7 days of culture. Data are compiled from 3 separate
experiments (* = p,0.05, compared to untreated group).
doi:10.1371/journal.pone.0009799.t001
Figure 3. Roscovitine dose response. Roscovitine was able to
trigger parthenogenic activation in rat oocytes. The difference between
the rate of activation in the 50 mM and 100 mM treatment conditions
was not significant. Data shown are compiled from three separate
experiments (* = p,0.05, compared to control group).
doi:10.1371/journal.pone.0009799.g003
Figure 4. Activation of rat oocytes with cyclin-dependent
kinase inhibitors. Approximately half the oocytes recovered from
each dissection were incubated with 5 mM calcium ionophore
ionomycin for 15 minutes preceding cyclin-dependent kinase inhibitor
treatment. Parthenogenic activation using CDKIs with ionomycin
pretreatment (68.1%) was more effective than no pretreatment
(36.1%). Data shown are compiled from five separate experiments
(* = p,0.05, compared to control group).
doi:10.1371/journal.pone.0009799.g004
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ionomycin pretreatment followed by exposure to a CDKI would
be an effective means of activating reconstructed rat embryos
(Table 2). Since the three CDKIs were all very similar in our
preliminary tests, we elected to examine bohemine in more detail,
as a representative example for a side by side comparison.
Parthenotes activated far more readily than reconstructed embryos
[x
2
(1)=26.2, p,0.01], by a more than 2:1 ratio (175/493, 35.5%
vs. 68/424, 16.0%). In contrast, reconstructed embryos were more
adversely affected by activation treatments [x
2
(1)=23.5, p,0.01]
than parthenotes by nearly the same margin (83/493, 16.8% vs.
148/424, 34.9%). This appeared to be a general phenomenon in
the reconstructed embryos. Although both strontium [x
2
(1)=37.1,
p,0.01] and I+DMAP [x
2
(1)=31.6, p,0.01] were very effective
at activating parthenotes, neither were effective for reconstructed
embryos. However, bohemine combined with ionomycin was
equally effective for both parthenotes [51.3%; x
2
(1)=34.2,
p,0.01] and reconstructed embryos [53.5%; x
2
(1)=47.9,
p,0.01]. After activation, and in a follow-up study, we continued
to culture rat embryos for an additional 5–7 days, to determine the
rate of blastocyst formation (Figure 5). Even in mR1ECM media,
widely considered the best for rat embryo culture, we estimate that
,2% of embryos are able to develop to this stage under these
culture conditions. We confirmed these observations by culturing
normal, fertilized rat oocytes collected from normally mated rats in
our animal colony. In data pooled from two separate experiments
using different batches of mR1ECM, only 2.6% progressed
beyond the 4-cell embryo stage (8/302), and only 1.3% (4/102)
progressed to blastocysts.
Discussion
Although there is a large, unmet need for genetically modified
rats (transgenic, knock-in and knock-out), such animals are rare.
The reason for this is simple: the various techniques used to make
genetically modified mice do not work as well in rats, are
extremely inefficient, or have proven technically unfeasible. Rat
embryonic stem (ES) cells are not widely available for gene
targeting approaches, and only recently has an ES cell-free
method for making knock-out rats been reported [40]. For
creating transgenic animals, pronuclear microinjection (PMI) is far
less efficient in rats as compared to mice, and most animal facilities
are not equipped to accommodate the large rat colonies necessary
for this trial and error approach. Other alternatives to PMI (e.g.,
lentiviral vectors) are unable to generate high expressing lines that
can be maintained over multiple generations [41], and are of
limited use. Thus in spite of a need for genetically modified rats as
an important alternative to mice, developing such models has
simply been beyond the reach of most investigators. The recent
development of nuclear transfer techniques to produce animals
from somatic cells offers a potential alternative to the traditional
approach to transgenesis. SCNT, or ‘‘cloning’’, has so far been
applied successfully to sheep [15,42], cattle [14,43], goats [31,44],
pigs [45,46], cats [47], rabbits [48] and mice [28], among others.
The technique has also been used to create genetically modified
animals [14,31,44,49,50]. However, adapting SCNT for use in the
rat has proven very difficult. To date, only a single report [24]
exists describing the successful generation of a rat by this method.
In this study, we report the use of cyclin-dependent kinase
inhibitors coupled with calcium ionophore treatment to achieve
the efficient activation of reconstructed rat embryos, a finding that
will improve the probability of eventually discovering the correct
combination of conditions for successful rat SCNT.
Figure 5. Culture and development of rat embryos. Left panels
illustrate parthenogenic and reconstructed embryo activation using the
calcium ionophore ionomycin followed by bohemine treatment. There
were no apparent differences between oocytes treated with 50 mM
versus 100 mM bohemine, and activated parthenotes were indistin-
guishable from activated reconstructed rat embryos (RERs). Right panels
illustrate the development of rat embryos in mR1ECM medium. Less
than 5% of rat embryos develop beyond the 4-cell stage, with only
,1% developing to the blastocyst stage (bottom panel, insert: arrow
indicates blastocyst inner cell mass).
doi:10.1371/journal.pone.0009799.g005
Table 2. Rat Oocyte Activation.
Parthenogenic:
Treatment Activated Degenerate
None 14/156 (9.0) 15/156 (9.6)
Sr
2+ 23/29 (79.3) ** 6/29 (20.7)
Ionomycin (I) 16/62 (25.8) 7/62 (11.3)
I + DMAP 61/127 (48.0) ** 21/127 (16.5)
I + Bohemine 61/119 (51.3) ** 34/119 (28.6) *
Reconstructed:
Treatment Activated Degenerate
None 11/188 (5.9) 62/188 (33.0)
Sr
2+ 6/70 (7.4) 31/70 (44.3)
Ionomycin (I) 2/30 (3.3) 3/30 (10.0)
I + DMAP 3/50 (6.0) 35/50 (70.0)
I + Bohemine 46/86 (53.5) ** 17/86 (19.8)
Activation data are the number of normal appearing 2–4 cell embryos after
24 hours/total (%). Degenerate embryos are those that exhibited extensive
fragmentation/uneven division of the ooplasm. Data are compiled from a
minimum of 3 separate experiments (* = p,0.05, **= p,0.01, compared to
untreated group).
doi:10.1371/journal.pone.0009799.t002
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to be an excellent method of activation for mouse reconstructed
embryos [28,51,52], but a poor method for rat reconstructed
embryos. Hence, activation methodology will not necessarily
translate between species,evenif theyareclosely related. Treatment
with strontium chloride was effective as an activator for both mouse
parthenotes and reconstructed embryos, and reconstructed mouse
embryos were able to develop to the blastocyst stage using this
treatment. This is in marked contrast to the results obtained in rat
embryos: activation levels induced by strontium chloride in rat
parthenotes were comparable to that of the mouse, but yet this
treatment could not activate reconstructed rat embryos. These
results are very similar to those of Hayes et al [20], who also had no
success with I+DMAP. This group was most successful at activating
rat embryos with an ethanol/cycloheximide treatment protocol,
although no live births were obtained. Cycloheximide is a
nonspecific inhibitor of protein synthesis, with activation being
induced indirectly through the inhibition of cyclin B production
[30,53]. Cycloheximidealso depletesthe oocyte of proteinsrequired
for DNA synthesis, resulting in abnormal DNA content and a
significant delay in development [54]. Even though ethanol/
cycloheximide has been used to clone cattle [55], post-implantation
development is poor, with NT embryos showing relatively high
levels of perinatal death and skeletal malformations [30,55]. It is
possible that the ethanol component of the activation protocol may
also contribute to difficulties in obtaining live offspring. Iannaccone
et al were able to successfully activate with strontium using a
different culture medium than Hayes et al, although they were also
unsuccessful at obtaining live animals [21].
These findings suggest that the somewhat crude methods of
activation that have been used in other species are inadequate for
rat nuclear transfer in general. DMAP is a general protein kinase
inhibitor that induces activation by preventing the phosphoryla-
tion of cdc25, which is normally responsible for activating MPF
[30]. However, DMAP is nonspecific, and will block numerous
other kinase activities, leading to the abnormal mobilization of
cytoskeletal components and premature mitosis [36]. Although the
I+DMAP protocol worked reasonably well in the case of
parthenogenic activation of oocytes, it mostly caused degeneration
when used to activate reconstructed embryos. In general, we found
that reconstructed embryos were more fragile than normal
embryos or parthenotes, consistent with other published observa-
tions [20,56,57]. We substituted more specific CDKIs for DMAP
in a similar protocol, and ultimately focused on bohemine. Unlike
the other activation strategies attempted, ionomycin followed by
bohemine resulted in similar rates of activation for both
parthenogenic and reconstructed embryos. Other reversible
CDKIs will likely be comparable to bohemine. It is possible that
activation rates may be further improved through the use of
alternative calcium ionophores, such as A23187 [58,59], or by
inhibitors of Ca
2+-dependent ATPases (e.g., thapsigargin [60]).
It has been shown that exposure to inorganic phosphate in the
media induces a block at the 2-cell stage in the rat embryo
[34,61,62]. To our knowledge, the best chemically defined medium
reported for the culture of rat embryos is mR1ECM [34], a
phosphate free media used in these studies. Rates of blastocyst
development in this media were poor, ,2% for both reconstructed
embryos and normally fertilized rat oocytes. In contrast, ,70% of
fertilized mouse oocytes typically reach the blastocyst stage when
cultured in KSOM [63]. It was recently reported that Sprague-
Dawley (SD) oocytes will develop to the blastocyst stage in
mR1ECM, but not those of four inbred rat strains [21]. However,
this same study also reported a rate of blastocyst formation for
reconstructed embryos of ,10%. Although LEH rats are also an
outbred strain, LEH derived embryos do not appear to fare as well
in vitro as those derived from the SD strain. It is possible that a
detailed, side-by-side comparison of LEH and SD oocytes may shed
light on the mechanism involved. It is clear that mR1ECM is an
inadequate media for the in vitro culture of reconstructed rat
embryos in general. It is possible that some of these issues might be
circumvented by transferring activated embryos to surrogate
mothers no later than the 2–4 cell stage, or possibly immediately
after exposure to activating conditions.
It may be possible to improve overall efficiency by performing
additional modifications to culture conditions. The simplest
alteration that has been successful in other systems has been the
use of feeder cell layers, such as embryonic rat fibroblasts or
buffalo rat liver (BRL) cells [64]. Feeder cells may release growth
factors into the media or assist in the removal of toxic substances,
and development rates can double or more in the presence of some
form of helper cell. The addition of insulin [65], vitamins [66], or
amino acids [63] might also be beneficial (insulin and amino acid
supplementation alone can triple the rate of rat blastocyst
development). Finally, serum is not a normal component of
mR1ECM. Since serum is a source of lipids, minerals and
hormones that are not present in normal media, the addition of a
small amount of either fetal bovine serum or normal rat serum
may dramatically improve in vitro development.
Numerous inefficiencies currently prevent the reproducible
implementation of rat SCNT. In this study we improved
substantially on existing methods of oocyte activation. However,
activation efficiency is only a single facet of the problem.
Inadequately definined culture conditions for rat embryos remains
a central issue. This is a major obstacle to making this technology
viable for rats, since rat embryos develop poorly in vitro. A better
understanding of rat oocyte physiology, also essential for
developing better models of disease, may also provide insights
that will be useful for making the SCNT process more efficient.
This approach may also be useful for embryos from other species
that prove less amenable to in vitro manipulation.
Acknowledgments
We thank Xin Yu for technical assistance with early studies, Brett Spear for
critical reading of the manuscript, and Todd E. Golde, James M. Robl and
Barry D. Bavister for helpful discussions and advice. We are grateful for
access to the equipment and resources of the UK and Mayo Clinic
transgenic core facilities.
Author Contributions
Conceived and designed the experiments: MPM. Performed the experi-
ments: RLW KAF MAG TLB MPM. Analyzed the data: MPM.
Contributed reagents/materials/analysis tools: MAG. Wrote the paper:
RLW TLB MPM.
References
1. Lipp H-P, Wolfer DP (1998) Genetically modified mice and cognition. Curr
Opin Neurobiol 8: 272–280.
2. Panitch HS, Hirsch RL, Haley AS, Johnson KP (1987) Exacerbations of
multiple sclerosis in patients treated with gamma interferon. Lancet 1: 893–
895.
3. Tanuma N, Shin T, Kogure K, Matsumoto Y (1999) Differential role of TNF-
alpha and IFN-gamma in the brain of rats with chronic relapsing autoimmune
encephalomyelitis. J Neuroimmunol 96: 73–79.
4. Ferber IA, Brocke S, Taylor-Edwards C, Ridgway W, Dinisco C, et al. (1996)
Mice with a disrupted IFN-gamma gene are susceptible to the induction
Activation of Rat Embryos
PLoS ONE | www.plosone.org 6 March 2010 | Volume 5 | Issue 3 | e9799of experimental autoimmune encephalomyelitis (EAE). J Immunol 156: 5–
7.
5. Gordon JW, Scangos GA, Plotkin DJ, Barbosa JA, Ruddle FH (1980) Genetic
transformation of mouse embryos by microinjection of purified DNA. Proc Natl
Acad Sci U S A 77: 7380–7384.
6. Wall RJ (2001) Pronuclear microinjection. Cloning Stem Cells 3: 209–220.
7. Siripattarapravat K, Pinmee B, Venta PJ, Chang CC, Cibelli JB (2009) Somatic
cell nuclear transfer in zebrafish. Nat Methods 6: 733–735.
8. Wani NA, Wernery U, Hassan FA, Wernery R, Skidmore JA (2009) Production
of the First Cloned Camel by Somatic Cell Nuclear Transfer. Biol Reprod.
9. Roh S, Choi HY, Park SK, Won C, Kim BW, et al. (2009) Porcine nuclear
transfer using somatic donor cells altered to express male germ cell function.
Reprod Fertil Dev 21: 882–891.
10. Kishigami S, Wakayama T (2009) Somatic cell nuclear transfer in the mouse.
Methods Mol Biol 518: 207–218.
11. Galli C, Lagutina I, Duchi R, Colleoni S, Lazzari G (2008) Somatic cell nuclear
transfer in horses. Reprod Domest Anim 43 Suppl 2: 331–337.
12. Li Z, Sun X, Chen J, Liu X, Wisely SM, et al. (2006) Cloned ferrets produced by
somatic cell nuclear transfer. Dev Biol 293: 439–448.
13. Colman A (1999) Somatic cell nuclear transfer in mammals: progress and
applications. Cloning 1: 185–200.
14. Cibelli JB, Stice SL, Golueke PJ, Kane JJ, Jerry J, et al. (1998) Cloned transgenic
calves produced from nonquiescent fetal fibroblasts. Science 280: 1256–
1258.
15. Campbell KH, McWhir J, Ritchie WA, Wilmut I (1996) Sheep cloned by
nuclear transfer from a cultured cell line. Nature 380: 64–66.
16. Filipiak WE, Saunders TL (2006) Advances in transgenic rat production.
Transgenic Res 15: 673–686.
17. Roh S, Malakooti N, Morrison JR, Trounson AO, Du ZT (2003) Partheno-
genetic activation of rat oocytes and their development (in vitro). Reprod Fertil
Dev 15: 135–140.
18. Yoo JG, Demers SP, Lian L, Smith LC (2007) Developmental arrest and
cytoskeletal anomalies of rat embryos reconstructed by somatic cell nuclear
transfer. Cloning Stem Cells 9: 382–393.
19. Shinozawa T, Mizutani E, Tomioka I, Kawahara M, Sasada H, et al. (2004)
Differential effect of recipient cytoplasm for microtubule organization and
preimplantation development in rat reconstituted embryos with two-cell
embryonic cell nuclear transfer. Mol Reprod Dev 68: 313–318.
20. Hayes E, Galea S, Verkuylen A, Pera M, Morrison J, et al. (2001) Nuclear
transfer of adult and genetically modified fetal cells in the rat. Physiol Genomics
5: 193–203.
21. Iannaccone P, Taborn G, Garton R (2001) Preimplantation and postimplanta-
tion development of rat embryos cloned with cumulus cells and fibroblasts.
Zygote 9: 135–143.
22. Krivokharchenko A, Popova E, Zaitseva I, Vil’ianovich L, Ganten D, et al.
(2003) Development of parthenogenetic rat embryos. Biol Reprod 68: 829–
836.
23. Mizutani E, Jiang JY, Mizuno S, Tomioka I, Shinozawa T, et al. (2004)
Determination of optimal conditions for parthenogenetic activation and
subsequent development of rat oocytes in vitro. J Reprod Dev 50: 139–146.
24. Zhou Q, Renard JP, Le Friec G, Brochard V, Beaujean N, et al. (2003)
Generation of fertile cloned rats by regulating oocyte activation. Science 302:
1179.
25. Ross PJ, Yabuuchi A, Cibelli JB (2006) Oocyte spontaneous activation in
different rat strains. Cloning Stem Cells 8: 275–282.
26. Tomioka I, Mizutani E, Yoshida T, Sugawara A, Inai K, et al. (2007) Spindle
formation and microtubule organization during first division in reconstructed rat
embryos produced by somatic cell nuclear transfer. J Reprod Dev 53: 835–
842.
27. Avery B, Hay-Schmidt A, Hyttel P, Greve T (1998) Embryo development,
oocyte morphology, and kinetics of meiotic maturation in bovine oocytes
exposed to 6-dimethylaminopurine prior to in vitro maturation. Mol Reprod
Dev 50: 334–344.
28. Wakayama T, Perry AC, Zuccotti M, Johnson KR, Yanagimachi R (1998) Full-
term development of mice from enucleated oocytes injected with cumulus cell
nuclei. Nature 394: 369–374.
29. Otaegui PJ, O’Neill GT, Wilmut I (1999) Parthenogenic activation of mouse
oocytes by exposure to strontium as a source of cytoplasts for nuclear transfer.
Cloning 1: 111–117.
30. Alberio R, Zakhartchenko V, Motlik J, Wolf E (2001) Mammalian oocyte
activation: lessons from the sperm and implications for nuclear transfer. Int J Dev
Biol 45: 797–809.
31. Keefer CL, Baldassarre H, Keyston R, Wang B, Bhatia B, et al. (2001)
Generation of dwarf goat (Capra hircus) clones following nuclear transfer with
transfected and nontransfected fetal fibroblasts and in vitro-matured oocytes.
Biol Reprod 64: 849–856.
32. Alberio R, Kubelka M, Zakhartchenko V, Hajduch M, Wolf E, et al. (2000)
Activation of bovine oocytes by specifc inhibition of cyclin-dependent kinases.
Mol Reprod Dev 55: 422–432.
33. Meijer L, Raymond E (2003) Roscovitine and other purines as kinase inhibitors.
From starfish oocytes to clinical trials. Acc Chem Res 36: 417–425.
34. Oh SH, Miyoshi K, Funahashi H (1998) Rat oocytes fertilized in modified rat 1-
cell embryo culture medium containing a high sodium chloride concentration
and bovine serum albumin maintain developmental ability to the blastocyst
stage. Biol Reprod 59: 884–889.
35. Holm S (1979) A Simple Sequentially Rejective Multiple Test Procedure.
Scand J Statist 6: 65–70.
36. Schlegal R, Belinsky GS, Harris MO (1990) Premature mitosis induced in
mammalian cells by the protein kinase inhibitors 2-aminopurine and 6-
dimethylaminopurine. Cell Growth Differentiation 1: 171–178.
37. Katoh M, Araki A, Ogura T, Valdivia RP (2004) 6-Dimethylaminopurine (6-
DMAP), which is used to produce most cloned animals, is mutagenic in
Salmonella typhimurium TA1535. Mutat Res 560: 199–201.
38. Koo OJ, Hossein MS, Hong SG, Martinez-Conejero JA, Lee BC (2009) Cell
cycle synchronization of canine ear fibroblasts for somatic cell nuclear transfer.
Zygote 17: 37–43.
39. Meijer L, Borgne A, Mulner O, Chong JP, Blow JJ, et al. (1997) Biochemical and
cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-
dependent kinases cdc2, cdk2 and cdk5. Eur J Biochem 243: 527–536.
40. Geurts AM, Cost GJ, Freyvert Y, Zeitler B, Miller JC, et al. (2009) Knockout
rats via embryo microinjection of zinc-finger nucleases. Science 325: 433.
41. Lois C, Hong EJ, Pease S, Brown EJ, Baltimore D (2002) Germline transmission
and tissue-specific expression of transgenes delivered by lentiviral vectors.
Science 295: 868–872.
42. Wilmut I, Schnieke AE, McWhir J, Kind AJ, Campbell KH (1997) Viable
offspring derived from fetal and adult mammalian cells [see comments]
[published erratum appears in Nature 1997 Mar 13;386(6621):200]. Nature
385: 810–813.
43. Kato Y, Tani T, Sotomaru Y, Kurokawa K, Kato J, et al. (1998) Eight calves
cloned from somatic cells of a single adult [see comments]. Science 282:
2095–2098.
44. Baguisi A, Behboodi E, Melican DT, Pollock JS, Destrempes MM, et al. (1999)
Production of goats by somatic cell nuclear transfer. Nature Biotechnology 17:
456–461.
45. Onishi A, Iwamoto M, Akita T, Mikawa S, Takeda K, et al. (2000) Pig cloning
by microinjection of fetal fibroblast nuclei. Science 289: 1188–1190.
46. Polejaeva IA, Chen SH, Vaught TD, Page RL, Mullins J, et al. (2000) Cloned
pigs produced by nuclear transfer from adult somatic cells. Nature 407: 86–90.
47. Shin T, Kraemer D, Pryor J, Liu L, Rugila J, et al. (2002) A cat cloned by
nuclear transplantation. Nature 415: 859.
48. Chesne P, Adenot PG, Viglietta C, Baratte M, Boulanger L, et al. (2002) Cloned
rabbits produced by nuclear transfer from adult somatic cells. Nat Biotech 20:
366–369.
49. McCreath KJ, Howcroft J, Campbell KH, Colman A, Schnieke AE, et al. (2000)
Production of gene-targeted sheep by nuclear transfer from cultured somatic
cells. Nature 405: 1066–1069.
50. Schnieke AE, Kind AJ, Ritchie WA, Mycock K, Scott AR, et al. (1997) Human
factor IX transgenic sheep produced by transfer of nuclei from transfected fetal
fibroblasts [see comments]. Science 278: 2130–2133.
51. Wakayama T, RodriguezI, PerryAC, Yanagimachi R, Mombaerts P (1999) Mice
cloned from embryonic stem cells. Proc Natl Acad Sci U S A 96: 14984–14989.
52. Wakayama T, Shinkai Y, Tamashiro KL, Niida H, Blanchard DC, et al. (2000)
Cloning of mice to six generations. Nature 407: 318–319.
53. Machaty Z, Prather RS (1998) Strategies for activating nuclear transfer oocytes.
Reprod Fertil Dev 10: 599–613.
54. Alberio R, Brero S, Motlik J, Wolf E, Zakhartchenko V (2001) Remodeling of
donor nuclei, DNA synthesis, and ploidy of bovine cumulus cell nuclear transfer
embryos: effect of activation protocol. Mol Reprod Dev 59: 371–379.
55. Zakhartchenko V, Mueller S, Alberio R, Schernthaner W, Stojkovic M, et al.
(2001) Nuclear transfer in cattle with non-transfected and transfected fetal or
cloned transgenic fetal and postnatal fibroblasts. Mol Reprod Dev 60: 362–369.
56. Heindryckx B, Rybouchkin A, Elst JVD, Dhont M (2001) Effect of culture media
on in vitro development of cloned mouse embryos. Cloning 3: 41–50.
57. Chung YG, Mann MRW, Bartolomei MS, Latham KE (2002) Nuclear-
cytoplasmic ‘‘tug of war’’ during cloning: effects of somatic cell nuclei on culture
medium preferences of preimplantation cloned mouse embryos. Biol Reprod 66:
1178–1184.
58. Wang W-H, Machaty Z, Ruddock N, Abeydeera LR, Boquest AC, et al. (1999)
Activation of porcine oocytes with calcium ionophore: effects of extracellular
calcium. Mol Reprod Dev 53: 99–107.
59. Tao T, Machaty Z, Abeydeera LR, Day BN, Prather RS (2000) Optimisation of
porcine oocyte activation following nuclear transfer. Zygote 8: 69–77.
60. Petr J, Rozinek J, Jilek F, Urbankova D (2000) Activation of porcine oocytes
using cyclopiazonic acid, an inhibitor of calcium-dependent ATPases. Journal of
Experimental Zoology 287: 304–315.
61. Matsumoto H, Sugawara S (1995) Development of rat embryos at the 1- and 2-
cell stage in modified HECM-1 medium after exposure to media that contain
phosphate. J Reprod Develop 41: 263–269.
62. Matsumoto H, Sugawara S (1998) Effect of phosphate on the second cleavage
division of the rat embryo. Hum Reprod 13: 398–402.
63. Biggers JD, McGinnis LK, Raffin M (2000) Amino acids and preimplantation
development of the mouse in protein-free potassium simplex optimized medium.
Biol Reprod 63: 281–293.
64. Ouhibi N, Sullivan NF, English J, Coleridge WH, Evans MJ, et al. (1995) Initial
culture behavior of rat blastocysts on selected feeder cell lines. Mol Reprod Dev
40: 311–324.
Activation of Rat Embryos
PLoS ONE | www.plosone.org 7 March 2010 | Volume 5 | Issue 3 | e979965. Zhang X, Armstrong DT (1990) Presence of amino acids and insulin in a
chemically defined medium improves development of 8-cell rat embryos in vitro
and subsequent implantation in vivo. Biol Reprod 42: 662–668.
66. Lane M, Gardner DK (1998) Amino acids and vitamins prevent culture-induced
metabolic perturbations and associated loss of viability of mouse blastocysts.
Hum Reprod 13: 991–997.
Activation of Rat Embryos
PLoS ONE | www.plosone.org 8 March 2010 | Volume 5 | Issue 3 | e9799